Systematic review: hydroxyurea for the treatment of adults with sickle cell disease. (yeni pencere açar)

Lanzkron S, Strouse JJ, Wilson R, Beach MC, Haywood C, Park H, Witkop C, Bass EB, Segal JB.

Kaynak‎: Ann Intern Med 2008;148(12):939-55.

İndeks‎: PubMed 18458272

https://www.ncbi.nlm.nih.gov/pubmed/18458272 (yeni pencere açar)

Cost-effectiveness of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. (yeni pencere açar)

Moore RD, Charache S, Terrin ML, Barton FB, Ballas SK.

Kaynak‎: Am J Hematol 2000;64(1):26-31.

İndeks‎: PubMed 10815784

https://www.ncbi.nlm.nih.gov/pubmed/10815784 (yeni pencere açar)

Hydroxyurea for the treatment of sickle cell anemia. (yeni pencere açar)

Platt OS.

Kaynak‎: N Engl J Med 2008;358(13):1362-9.

İndeks‎: PubMed 18367739

DOI‎: 10.1056/NEJMct0708272

https://www.ncbi.nlm.nih.gov/pubmed/18367739 (yeni pencere açar)

Clinical effectiveness of decitabine in severe sickle cell disease. (yeni pencere açar)

Saunthararajah Y, Molokie R, Saraf S, Sidhwani S, Gowhari M, Vara S, Lavelle D, DeSimone J.

Kaynak‎: Br J Haematol 2008;141(1):126-9.

İndeks‎: PubMed 18324975

DOI‎: 10.1111/j.1365-2141.2008.07027.x

https://www.ncbi.nlm.nih.gov/pubmed/18324975 (yeni pencere açar)

The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). (yeni pencere açar)

Voskaridou E, Christoulas D, Bilalis A, Plata E, Varvagiannis K, Stamatopoulos G, Sinopoulou K, Balassopoulou A, Loukopoulos D, Terpos E.

Kaynak‎: Blood 2010;115(12):2354-63.

İndeks‎: PubMed 19903897

DOI‎: 10.1182/blood-2009-05-221333

https://www.ncbi.nlm.nih.gov/pubmed/19903897 (yeni pencere açar)

Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease. (yeni pencere açar)

Hirst C, Owusu-Ofori S.

Kaynak‎: Cochrane Database Syst Rev 2012;(9):CD003427.

İndeks‎: PubMed 22972063

DOI‎: 10.1002/14651858.CD003427.pub2

https://www.ncbi.nlm.nih.gov/pubmed/22972063 (yeni pencere açar)

Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial. (yeni pencere açar)

Howard J, Ataga KI, Brown RC, Achebe M, Nduba V, El-Beshlawy A, Hassab H, Agodoa I, Tonda M, Gray S, Lehrer-Graiwer J, Vichinsky E

Kaynak‎: Lancet Haematol 2021;8(5):e323-33.

İndeks‎: PubMed 33838113

DOI‎: 10.1016/S2352-3026(21)00059-4

https://www.ncbi.nlm.nih.gov/pubmed/33838113 (yeni pencere açar)

Sickle cell disease. (yeni pencere açar)

Meremikwu MM, Okomo U.

Kaynak‎: BMJ Clin Evid 2011;02:2402.

İndeks‎: PubMed 21718552

https://www.ncbi.nlm.nih.gov/pubmed/21718552 (yeni pencere açar)

A phase 3 trial of l-glutamine in sickle cell disease. (yeni pencere açar)

Niihara Y, Miller ST, Kanter J, Lanzkron S, Smith WR, Hsu LL, Gordeuk VR, Viswanathan K, Sarnaik S, Osunkwo I, Guillaume E, Sadanandan S, Sieger L, Lasky JL, Panosyan EH, Blake OA, New TN, Bellevue R, Tran LT, Razon RL, Stark CW, Neumayr LD, Vichinsky EP

Kaynak‎: N Engl J Med 2018;379(3):226-35.

İndeks‎: PubMed 30021096

DOI‎: 10.1056/NEJMoa1715971

https://www.ncbi.nlm.nih.gov/pubmed/30021096 (yeni pencere açar)

Malaria chemoprophylaxis in sickle cell disease. (yeni pencere açar)

Oniyangi O, Omari AA.

Kaynak‎: Cochrane Database Syst Rev 2006;(4):CD003489.

İndeks‎: PubMed 17054173

DOI‎: 10.1002/14651858.CD003489.pub2

https://www.ncbi.nlm.nih.gov/pubmed/17054173 (yeni pencere açar)